Abstract 273P
Background
The nuclear factor-κB (NF-κB) pathway has been considered an essential and tightly regulated signaling cascade that mediates the development, activation, and survival of lymphocytes for regulated immune responses. Moreover, many of the oncogenic mediators involved in the pathology of lymphoma are regulated by NF-κB. Abnormal NF-κB activation occurs during many pathological conditions. A20 (intracellular ubiquitin-editing protein) is a negative feedback regulator of NF-κB signaling. A20 was identified as a MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) substrate, and MALT1 can cleave A20 to impair its NF-κB inhibitory function.
Methods
This study was carried out on 100 subjects classified into the following groups: Group I: included 80 patients with Non-Hodgkin Lymphoma (NHL). Group II: Included 20 ages and sex matched healthy individuals as a control group. All participants were subjected to full history taking and clinical examination. All NHL cases were subjected to abdominal ultrasound & CT-scan for abdomen and metastatic work up: chest x-ray and bone scan. Blood sample were taken for CBC, ESR, Serum LDH and β2 microglobulin (β2M) levels and detection of MALT1, A20 and NF-κB genes expression in cDNA samples extracted from RNA samples by reverse transcription by using real time PCR using SYBR Green technique.
Results
There was significant statistical increased expression of MALT1 and NF-κB and significant statistical decreased expression of A20 in NHL cases when compared with control. In NHL patients there was significant statistical decreased expression of MALT1, A20 and NF-κBin (HCV +ve) NHL cases when compared with controls and there was significant statistical increased expression of MALT1 and NF-κBand significant statistical decreased expression of A20 in (HCV-ve) NHL cases when compared with controls.
Conclusions
MALT1- A20 and NF-κB have specific expression pattern in patients with Non Hodgkin Lymphomas.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufia university.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract